The implementation of end-user licensing agreements is sometimes questioned. Just as pharmaceutical companies are always looking for the next drug to counterbuster, investors are looking for the company that will develop it. This is why licensing agreements can be somewhat of a deterrent – even if a drug proves to be extremely effective, its profits must be shared between two pharmaceutical companies and therefore between two groups of shareholders. License agreements limit the conditions under which one party may use another party`s property. While the real estate in question can encompass a large number of objects, including real and personal property, licensing agreements are most often used for intellectual property, such as patents and trademarks, as well as copyrights for written materials and visual arts. In a typical license agreement, the licensor undertakes to make available to the licensee intellectual property rights such as the licensor`s technology, trademark or know-how. In exchange for the licensor`s intellectual property, the licensee generally applies to a prior royalty and/or a royalty to the licensor. A royalty is a current royalty paid for the licensor`s right to use the intellectual property. Under an outright license agreement, the licensor may, under its terms and in accordance with customary law, terminate the contract after authorization and without justification, unless it is linked to an interest or made irrevocable by contract. An interest-related licence may not be revoked by the licensor without liability and potential damage having been received.
In the event that a licence is of interest, the licensor must give the licensee a reasonable period of time to remove that interest from the property before termination. Since a licence does not confer a right of ownership on the licensee, the licence is terminated in the event of sale of the property and cannot be imposed on the new owners of the property. In addition, the death of the licensee or licensor terminates the contract. Exclusivity and territory. The licensee has the exclusive right to manufacture and sell the product in a given territory. Licensor undertakes not to allow anyone to sell the product in that region. This part of the agreement is usually accompanied by a duration. Today, licensing can be the preferred mode of commercial development for the pharmaceutical industry. Should this affect your investment strategy? As part of the licensing agreement, the two companies will support the development and commercialization of ciraparantag in Europe, Australia and New Zealand. The candidate aims to reverse the anticoagulant effect of direct oral anticoagulants and low molecular heparin in patients who use these products and who require emergency surgery or who experience uncontrolled life-threatening bleeding. Ciraparamtag restores the body`s ability to form blood clots.
A licence shall be issued by a party of another Party under an agreement between those parties. . . .
